This article is more than 5 years old. Information may no longer be current.

pSivida reports net loss for second quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

pSivida reported a net loss of $3.5 million, or $0.13 per share, for its second quarter, according to a press release.

This compares with a net loss of $2.6 million, or $0.11 per share, for the same quarter the previous year.

The loss was primarily attributed to costs associated with the company’s continuing involvement in a phase 3 clinical trial of Medidur for posterior uveitis.

Quarterly revenue was $592,000, an increase from $585,000 reported for the same period in 2012.